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Dithiocarbamates (DTCs) are chemically referred to as 
functional groups analogs to the carbamates, containing 
sulfur instead of oxygen atoms. Herein we report the 
kinetic results of a series of DTC-containing compounds 
tested on α and β-carbonic anhydrases (EC 4.2.1.1). The 
DTCs binding mode was also investigated by means of 
crystallographic experiments of the selected DTC 10, 11 
and 14 in adduct with human carbonic anhydrase II.
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Dithiocarbamates (DTCs) are chemically referred to as functional group 
analogs to the carbamates, containing two sulfur atoms instead of oxygen 
atoms. DTCs are stable in the form of both inorganic and organic salts or 
esters, and are easily obtained by coupling reactions of primary/secondary 
amines (aliphatic or aromatic) with carbon disulfide in the presence of an 
appropriate base. The introduction of an alkyl halide in the reaction 
medium affords the corresponding esters [1]. The use of DTC-bearing com-
pounds in large amounts began in the early 20th century, with their indus-
trial application as accelerators in the rubber vulcanization process [1]. This 
method proved to be much more efficient than the primitive, sulfur-based 
procedures introduced by Goodyear and Hancock approximately 60 years 
earlier [1]. Actually many DTCs are widely used in different fields such as in 
the analytical, macromolecular and organic chemistry, medicine and biol-
ogy [1]. Undoubtedly the plant disease management is the area in which 
DTCs are predominantly employed [1]. The role DTCs play nowadays is head-
ing for strengthening in the near future, due to the global growth popula-
tion estimations (∼9 billion in 2050) and the necessity to control plant 
diseases by means of chemical agents [1,2].
DTCs & the carbonic anhydrases
The main feature of DTCs is the ability to form stable complexes with metal 
ions, and plenty of reports accounting for the characterization of such 
derivatives are available in the literature [1]. However, the first study deal-
ing with DTCs and metalloenzymes only appeared in 1983 with the inves-
tigation of the interaction between N,N-diethyldithiocarbamate 1 and 
various metal-containing bovine carbonic anhydrases (bCAs) [3]. In par-
ticular, the study reported the enzymatic inhibition of 1 with the native 
zinc-containing bCA, the ability of 1 to extrude the catalytic metal ion from 
the enzymatic site, and the authors proposed a trigonal bipyramidal geom-
etry for the 1-Co(II)-bCA adduct [3]. However the scientific community 
ignored the topic until the kinetic profiles of a series of unexplored inor-
ganic anions on the human (h) and murine (m) CAs (EC 4.2.1.1) were 
recently reported by our group [4,5]. Such results demonstrated that most 
common inorganic anions explored [6], pos-
sess inhibition constants (Kis) between the 
millimolar to the sub-millimolar range. It is 
worth mentioning that the cyanide, azide 
and hydrogen sulfide were the only known 
exceptions [6]. Among the newly investi-
gated inorganic species, trithiocarbonate 2 
showed the highest affinities (Kis 8.7, 9.9, 
Dithiocarbamates (DTCs): chemically referred 
as functional groups analogs to the carbamates, 
containing two sulfur instead of oxygen atoms.
Carbonic anhydrase inhibitors (CAIs): in general 
referred as chemical species able to inhibit the activity 
of the carbonic anhydrase enzymes. Classical CAIs 
include the sulfonamides and their bioisosters the 
sulfamates and the sulfamides.
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9.7 and 120 µM) for various CA isoforms, such as hCA I, II, IX and XII, 
respectively (Table 8.1) [4,5]. These studies validated trithiocarbonate 2 as 
a new inorganic CA inhibitor (CAI) and its binding mode was then explored 
by means of x-ray crystallography on the 2-hCA II adduct [7]. Along with 
trithiocarbonate 2 the kinetic studies were also extended to the organic, 
structurally related compound N,N-diethyldithiocarbamate 1. The ration-
ale of this investigation was to explore whether organic compounds incor-
porating the trithiocarbonate moiety merged into organic scaffolds, such 
as the DTCs, might act as CAIs. The known metal chelating properties of 
the DTCs and the preliminary investigations by Morpurgo et al. previously 
discussed, indeed represented an interesting starting point to validate 
such a hypothesis. Indeed, we definitely proved that N,N-diethyldithio-
carbamate 1 not only efficiently inhibits hCAs but it is even a better inhib-
itor when compared with its inorganic lead trithiocarbonate 2, having Ki 
values as low as 24.6-times those for the hCA VII [4,5]. Afterwards, we 
reported a series of new DTC derivatives 3–28, which have been prepared 
and screened for their inhibition activities on several α- and β-CAs. The 
biological implications as well as structure–activity relationship (SAR) 
investigations will be developed later in this chapter, now it is important 
to focus on the DTCs binding mode, which was explored by means of x-ray 
crystallography on adducts of several such DTCs, that is, 10, 11 and 14, 
bound to hCA II (Figure 8.1) [8,9]. 
The DTCs were found deeply buried into the enzyme active site. The CS2
- 
groups upon displacement of the zinc-bound water/hydroxide, directly 
interacted through a sulfur atom with the catalytic zinc ion at a distance 
Zn-S of 2.3 Å. The angles defined by the zinc-coordinating histidines (His94, 
His96 and His119), the metal ion and the DTCs sulfur atom closely associ-
ated, account for a distorted tetrahedral geometry, which resembles the 
binding mode of the classical CAIs, such as the sulfonamides and their 
bioisosters sulfamates and sulfamides (Figure 8.1A–8.1C) [8,9]. The major 
differences in the interaction modes of 10, 11 and 14 with the hCA occur 
at the organic scaffold level. The benzyl ring of compound 14 engages a 
T-shaped π-staking interaction with the imidazole ring of the His64, which, 
as a result, was frozen in the ‘in’ conformation. Furthermore, 14 is stabilized 
by the weaker van der Waals interactions occurring with the side chains of 
Asn62, Glu92, His94, Val121, Phe131, Leu198, Thr200 and Pro202 
(Figure 8.1C) [8,9]. On the other hand, compound 10 positioned its phenyl 
ring onto a hydrophobic pocket located at the opposite site of the enzy-
matic tunnel bearing the His64 residue (Figure 8.1A) [8,9]. The pendant 
His64 imidazole ring was at a distance of 5 Å from 10, being thus not 
involved in any valuable interaction with the inhibitor and is allowed to flip 
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adopting both the ‘in’ and ‘out’ confor-
mations. The phenyl ring of 10 headed 
towards the rim of the catalytic cleft, 
interacting with Phe131 and Pro202, 
whereas the cyano group hydrogen 
bonds with Asn67 and Gln 92 and a water 
molecule locate nearby (Figure 8.1A) [8,9]. 
Compound 11 was the deepest buried 
among all, and, as for compound 10, no 
interactions with the His64 side chain 
occurred. The only contacts detected for 
the compound 11 scaffold in adduct with 
hCA II were with two water molecules, 
Wat393 and 540 (Figure 8.1B) [8,9]. 
The inhibition profiles of the DTCs 1 and 
3–28 on hCA I, II, IX and XII are reported 
in Table 8.1 and compared with the 
acetazolamide (AAZ) as CAI reference 
compound [8].
Compounds 1 and 3 are less effective as 
CAIs against all the screened isoforms. 
The elongation of both the aliphatic 
chains, as for 4–6, ensures a progressive 
amelioration in the affinities toward all 
hCA isozymes tested, with Kis in the range 
of 5.8–1838 nM. A slight selectivity of 4 
and 5 for the tumor-associated isoform 
hCA XII is observed (Kis 7.0 and 5.8 nM for 
4 and 5, respectively). The introduction 
of terminal hydroxide groups, as in 7, 
results into an overall improvement of 
the CA inhibitions (Ki 4.0–9.2 nM) and 
further enhancements are gained when 
the linear side chains are substituted with 
branched analogs as in 8. The Ki values for 
the i-Bu 8 were lower of one or two order 
of magnitude compared with the parent 
linear compound 5 (Kis 0.97, 0.95, 4.5 and 
0.99 nM for 8 and Kis 43.1, 50.9, 50.3 and 
5.8 nM for 5 on hCA I, II, IX and XII, respec-
tively). The idea to join the linear alkyl Fi
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Table 8.1. Human carbonic anhydrase I, II, IX and XII inhibition data with 
dithiocarbamates 1, 3–28 and trithiocarbonate 2.
Compound R1 R2 Ki (nM)
hCA I hCA II hCA IX hCA XII
1 Et Et 790 3100 1413 11
2† CS
3
- 8.7 × 103 9.9 × 103 9.7 × 103 120 × 103
3 Me Me 699 6910 714 798
4 n-Pr n-Pr 1838 55.5 53.8 7.0
5 n-Bu n-Bu 43.1 50.9 50.3 5.8
6 n-Hex n-Hex 48.0 51.3 27.4 16.1
7 HOCH2CH2 HOCH2CH2 9.2 4.0 4.3 4.2
8 i-Bu i-Bu 0.97 0.95 4.5 0.99
9 (CH2)5 0.96 27.5 70.4 46.1
10 (NC)(Ph)C(CH2CH2)2 48.4 40.8 757 169
11 O[(CH2CH2)]2 0.88 0.95 6.2 3.4
12 Et n-Bu 157 27.8 25.9 7.5
13 Me Ph 39.6 21.5 28.2 7.7
14 Me PhCH2 69.9 25.4 53.0 3.0
15 H sec-butyl 21.1 29.4 4.6 31.7
16 H Ph 4.8 4.5 4.2 4.3
17 H 2-thiazolyl 3.9 4.6 12.6 22.0
18 H PhCH2 4.1 0.7 19.2 11.5
19 H 4-PyridylCH2 3.5 16.6 26.0 24.1
20 H Imidazol-1-yl-(CH2)3 8.6 24.7 4.3 6.5
21 H O[(CH2CH2)]2N 4.8 3.6 29.1 9.2
22 H O[(CH2CH2)]2N(CH2)2 31.8 36.3 4.5 4.2
23 H [(CH2)5N]CH2CH2 4.5 20.3 3.6 20.5
24 H MeN[(CH2CH2)]2N 33.5 33.0 22.1 17.5
25 NaS(S=C)N[(CH2CH2)]2 12.6 0.92 37.5 0.78
26 H KOOCCH2 13.1 325 57.1 6.7
27 (S)-[CH2CH2CH2CH(COONa)] 2.5 17.3 4.1 4.0
28 H N[(CH2CH2)N]3 31.9 13.5 27.4 9.3
AAZ 250 12 25 5.7
†hCA III, VII and XIII not shown. 
Reproduced with permission from [8] © American Chemical Society (2012).
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chains by means of a -CH2- (compound 9), ends in affinity values similar to 
the best alkyl derivative 8 only for the cytosolic hCA I, whereas the other 
isoforms keep their Ki closer to the linear DTCs 4–6 (Kis 0.96, 27.5, 70.4 and 
46.1 nM for 9 on hCA I, II, IX and XII, respectively) (Table 8.1). The substitu-
tion of the joint -CH2-protons with bulkier groups (compound 10) causes a 
sensible drop in the inhibitory activities (Kis 48.4, 40.8, 757 and 169 nM for 
10 on hCA I, II, IX and XII, respectively). On the other end, replacement of 
the -CH2- with a sp
3-hybridized oxygen, as in 11, greatly enhances the enzy-
matic affinities (Kis 0.88, 0.95, 6.2 and 3.4 nM on hCA I, II, IX and XII, respec-
tively). The asymmetric N,N-disubstituted DTCs 12, 13 and 14 preferentially 
inhibit the tumor-associated hCA XII isoform (Kis 7.5, 7.7 and 3.0 nM for 12, 
13 and 14, respectively, on hCA XII). The monosubstituted sec-butyl deriv-
ative 15 has inhibition values comprised between the parent linear N,N-
dialkylated 5 and the branched 8 (Kis 21.1, 29.4, 4.6 and 31.7 nM for 15 on 
hCA I, II, IX and XII, respectively). When an aromatic moiety is introduced, 
such as the phenyl ring in 16 or the heterocyclic thiazolyl group in 17, the 
Ki values get flattened to the low nanomolar levels, and only a minor selec-
tivity for the hCA I and hCA II is observed for 17 (Table 8.1). The insertion 
of a spacer between the aromatic/heteroaroamatic tail and the DTC nitro-
gen (compounds 18, 19 and 20) did not improve the inhibition profiles 
(Table 8.1). Interestingly, the morpholine compound 21 showed preferen-
tial inhibition for the cytosolic hCA I and II, whereas the introduction of an 
ethylenic spacer (compound 22) shifted the selectivity toward the tumor-
associated isoforms hCA IX and XII. The replacement of the morpholinic 
oxygen in 22 with a -CH2- , to give 23, lowers the hCA I and IX Ki values of 
4.5- and 5.7-fold compared with the corresponding cytosolic hCA II and 
tumor-associated hCA XII isoforms. The bis DTC 25 had a complementary 
kinetic profile to 23, as shows stronger affinity for the hCA II and XII over 
the corresponding hCA I and IX (Table 8.1). The aminoacidic derivatives 
glycine 26 and S-proline 27 were screened for their inhibitory activities. In 
particular 26 badly interacts with the hCA II (Ki of 325 nM). Despite the 
S-proline 27 reported Ki values at the low nanomolar level for all the tested 
hCAs, in analogy to 26, keeps the inhibition for hCA II weaker (Table 8.1). 
In conclusion the SAR of compounds 1 and 3–28 validated the DTCs as new 
class of CAIs, having inhibition constants 
spanning from the micro- to the nano-molar 
range. 
In light of such considerations DTCs 11 and 
25 were investigated for their intraocular 
pressure (IOP) inhibition properties on the 
carbomer-induced glaucoma model on 
Glaucoma: consists of a group of progressive 
optic neuropathies characterized by a slow and 
progressive degeneration of retinal ganglion cells and 
their axons. It shows a broad spectrum of clinical 
presentation and etiologies, which lead to a 
permanent loss of visual function due to the damage 
of the optical nerve. Most types of glaucoma are 
characterized by an elevated intraocular pressure.
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rabbits, and compared with the standard clinically used dorzolamide (DRZ) 
[8]. Glaucoma is estimated to affect more than 70 million people worldwide 
and is clinically characterized by a series of neuropathic diseases, which 
progressively affect the retinal systems toward irreversible visual impair-
ment and blindness [6,10,11]. The majority of glaucomas are characterized 
by elevated IOPs as result of unbalance between flow-out and production 
of the aqueous humor [6,10,11]. The metalloenzyme CAs plays a crucial role 
in the production of the aqueous humor, which is particularly rich in the 
bicarbonate ions [6,10], and the pioneering report of Becker in 1955 created 
the base for the use of CAIs as antiglaucoma agents [12].
As previously discussed DTCs take part in the CA catalytic cycle in the same 
manner as the classical CAIs such as sulfonamides and their bioisosters, to 
afford the intermediate E in Figure 8.2 [13]
The result is the interruption of the CAs catalytic cycle with a diminished 
production of bicarbonate and protons as in agreement with CO2 + H2O ⇋ 
HCO
3
- + H+. The biological consequences are a lower production of the 
Figure 8.2. Catalytic cycle of human carbonic anhydrases.
lnh-
Zn
2+
His96
His94
Zn
2+
His119
His96
His94
H2O lnh
-
Zn
2+
His96
His94
His119
O
O-
OH
OH-
Zn
2+
His119
His
His119
His
OH-
Zn
2+
His96
94
His119
OH2
Zn
2+
His96
His94
His119
96
His94
O
O
InhH - H+
+ H2O
- HCO3
-
+ CO2
+ InhH
- H2O
- BH+
Hydrophobic pocket
Val 121
Val 143
Leu 198
A
B
B
C
D
E
F
Data taken from [13].
Carta, Bozdag, Tanc & Supuran
122 www.future-science.com
humor liquid and IOP lowering as demonstrated by the Figure 8.3 referred 
to 11 and 25 used at 2% concentration [8]. Both compounds show a persis-
tent IOP lowering effect up to 8 h after local administration with 11 been 
slightly the more potent. In any case both DTCs 11 and 25 proved to be 
superior in terms of potency and lasting to the clinically used DRZ at the 
same concentration [8]. 
DTCs & α-CAs from Drosphila melanogaster
The arthropod Drosophila melanogaster, also known as fruit fly, became of 
particular attention as it represented the first animal, along with the nema-
tode Caenorhabditis elegans, in which the presence of a β-class CA (DmBCA) 
was reported [14,15]. CA enzymes are classified into five unrelated gene 
families (α-, β-, γ-, δ- and ζ) and usually it is assumed that each CA-class is 
expressed only within specific species [6]. Despite the new scientific findings, 
little is known about the properties of the α-CAs abundantly expressed in 
D. melanogaster. A study of this kind recently appeared [16], and it reported 
the expression, purification and characterization of the D. melanogaster 
CAH1 and CAH2 along with their tissue distributions. Both enzymes were 
also considered for their carbon dioxide hydration reaction activities by 
means of stopped-flow measurements. Interestingly CAH1 and CAH2 
revealed high catalytic turnovers with values similar to the highly active hCA 
II, but slightly lower when compared with the DmBCA (6.4 × 106 for CAH1, 
Figure 8.3. 48 h intraocular pressure monitoring of compounds 11 and 25 at 2% concentration in 
aqueous solution. 
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6.0 × 106 for CAH1, 9.5 × 105 for DmBCA and 1.4 × 106 for hCA II) [14,16]. CAH1 
and CAH2 are efficiently inhibited by the CAI acetazolamide (AAZ), even if 
with Kis higher than the hCA II and DmBCA values (Kis 106, 78, 49 and 12 nM 
for AAZ on CAH1, CAH1, DmBCA and hCA II, respectively) [14,16]. 
The DTCs 1 and 3–28 previous reported were also screened for their inhibi-
tion profiles on both CAH1 and CAH2, and their data were compared with 
the hCA II Ki values obtained in the same conditions (Table 8.2) [16]. A general 
overview reveals that all DTCs tested have good inhibition properties, with 
the only exceptions of 1 and 3 been the less active in the series (Table 8.2). 
Elongation of the aliphatic chains as in 4–6 drives the selectivity toward 
CAH2 over CAH1 and hCA II (Table 8.2). Similarly 10, the N-monosubsti-
tuted DTC 15, and the tris-DTC 28 show analogous inhibition profiles. On 
the other hand the heterocyclic thiazolyl derivative 17, the methyl pipera-
zine 24 and S-proline 27 have preferential inhibition for the CAH1 over the 
other tested isozymes. The kinetic investigation reported is of particular 
importance as subcellular localization predictions account for the cyto-
plasmic and extracellular membrane-bounded expression of CAH1 and 
CAH2, respectively [16]. Moreover, in support of the localization predictions, 
the phylogenetic tree reveals CAH1 sharing a common ancestor with the 
cytosolic hCA I and hCA II, whereas CAH2 been related to the extracellular 
human isoforms [16]. Thus compounds, as the DTCs, which show selectivity 
for specific arthropod CAs, are of particular relevance for the management 
of parasites or organisms acting as vectors for potential diseases. 
DTCs as new β-CAIs
The β-CAs, in agreement with their primordial origins, are largely encoded 
in archaea, bacteria, algae and fungi. In this contest is important to consider 
the problems associated to the management of diseases directly provoked 
of transmitted by such organisms [6,17]. Moreover the appearance of drug-
resistant (DR) and multiple drug-resistant (MDR) bacteria are the principal 
causes of failure in the treatment of infections. Nevertheless, the US FDA 
registered a drop in the approval of new drugs as antibacterials up to 56% 
in the last 20 years [17]. Therefore, the selective targeting of the β-CAs 
represents a very promising approach for the development of new anti-
infectives, and the validation of the DTCs as new CAIs indeed might provide 
such opportunity. 
The Mycobacterium tuberculosis genome encodes for three β-CAs (mtCA1, 
mtCA2 and mtCA3) [18,19]. The bacterial 
enzymes have been cloned, characterized 
and screened for their kinetic profiles with 
Anti-infectives: molecules of natural or 
synthetic origin able to suppress micro-
organisms dangerous for human health.
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Table 8.2. hCA II, CAH1 and CAH2 inhibition data with dithiocarbamates 1 and 3–28.
Compound R1 R2 Ki (nM)
hCA II CAH1 CAH2
1 Et Et 3100 2355 654
3 Me Me 6910 3461 769
4 n-Pr n-Pr 55.5 23.4 3.9
5 n-Bu n-Bu 50.9 17.1 0.5
6 n-Hex n-Hex 51.3 1.4 3.8
7 HOCH2CH2 HOCH2CH2 4.0 3.2 134
8 i-Bu i-Bu 0.95 20.2 0.9
9 (CH2)5 27.5 135 4.7
10 (NC)(Ph)C(CH2CH2)2 40.8 12.8 3.7
11 O[(CH2CH2)]2 0.95 13.8 0.8
12 Et n-Bu 27.8 10.5 21.9
13 Me Ph 21.5 67.1 5.9
14 Me PhCH2 25.4 50.2 12.4
15 H sec-butyl 29.4 325 0.9
16 H Ph 4.5 21.4 33.9
17 H 2-thiazolyl 4.6 0.5 3.9
18 H PhCH2 0.7 0.8 213
19 H 4-PyridylCH2 16.6 35.1 58.8
20 H Imidazol-1-yl-(CH2)3 24.7 0.9 24.1
21 H O[(CH2CH2)]2N 3.6 13.1 20.7
22 H O[(CH2CH2)]2N(CH2)2 36.3 12.1 10.4
23 H [(CH2)5N]CH2CH2 20.3 57.1 26.7
24 H MeN[(CH2CH2)]2N 33.0 0.9 13.8
25 NaS(S=C)N[(CH2CH2)]2 0.92 0.9 21.6
26 H KOOCCH2 325 12.3 76.5
27 (S)-[CH2CH2CH2CH(COONa)] 17.3 1.4 13.6
28 H N[(CH2CH2)N]3 13.5 134 1.5
AAZ 12 106 78
Reproduced with permission from [16]. © Elsevier (2013).
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classical CAIs as the sulfonamides [19–21]. DTCs 1 and 3–27 were investi-
gated for their ability to inhibit mtCA1 and mtCA3 and the results are 
reported below in comparison with the cytosolic human hCA I and hCA II 
(Table 8.3) [22].
Table 8.3 shows that almost all tested DTCs have good affinities for both 
the mtCA1 and mtCA3, with Kis spanning from 0.9 to 893 nM. Similarly to 
the human cytosolic isozymes hCAI and hCA II, compounds 1 and 3 were 
the less active (Kis 431–893 nM). Chain elongation, as for 4–6, accounts 
for a slightly preferential inhibition of the mtCA3 isoform over the mtCA1 
(Table 8.3). Such effect becomes more evident when the branched i-Bu 
substituents are present (Kis 86.2, 43.0 nM for 8 on mtCA1 and mtCA3, 
respectively). The introduction of the hydroxyl functionalities, as for com-
pound 7, results in an overall enhancement of the mtCAs inhibitory prop-
erties (Kis 7.5, 6.0 nM for 7 on mtCA1 and mtCA3, respectively). Inclusion 
of the DTC nitrogen into a cyclohexane ring, as in 9, shifts the inhibition 
toward the mtCA3 isozyme over the mtCA1 (Kis 90.5, 4.1 nM for 9 on 
mtCA1 and mtCA3, respectively). Interestingly the substitution in 9 of the 
distal -CH2- with an oxygen (compound 11) lowers both the mtCAs Ki values, 
and it completely abolishes any preferential inhibition. Also the asymmet-
ric N,N-disubstituted DTCs 12–14 show good inhibition with Kis comprised 
between 25.2 and 91.6 nM. The N-monosubstituted DTCs 15, 16, 19, 20–24 
reveal better profiles among all the series having Kis in the low nanomolar 
range and comprised between 2.4 and 9.1 nM. Interestingly, 17 and 18 are 
9.4- and 12.3-fold more selective toward the mtCA3 and mtCA1, respec-
tively (Table 8.3). The bis-DTC 25 offers better selectivity when compared 
with 17, as possesses a Ki for the mtCA3 48-times lower to the correspond-
ing for mtCA1. Finally the amino acidic derivatives 26, 27 and the tris-DTC 
28 are good mtCAs inhibitors with Kis between 4.0 and 8.0 nM
As for the M. tuberculosis, the β-CAs from the pathogenic fungi Cryptococ-
cus neoformans, Candida albicans and Candida glabrata (Can2, CaNce103 
and CgNce103) were investigated for their inhibition profile with DTCs 1, 
3–28 (Table 8.4) [23].
In general, all tested compounds show good inhibition profiles towards all 
three fungal CAs, with the smaller derivatives 1 and 3 being the less active 
in the series (Kis 962–802 nM). Again the chain elongation, as for com-
pounds 4–6, or the introduction of the branched i-Bu substituents (as for 
8) lowered the enzymatic Kis up to low nanomolar values (Table 8.4). In 
particular the n-hexyl-disubstituted DTC derivative 6 had the lowest Ki ever 
reported for Can2 (Ki 0.75 nM). Among the remaining N,N-disubstituted 
derivatives 7 and 9–14, compounds 10 and 14 have the better affinities (Kis 
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Table 8.3. hCAI, II, mtCA 1 and mtCA 3 inhibition data with dithiocarbamates 1, 3–28.
Compound R1 R2 Ki (nM)
hCA I hCA II mtCA 1 mtCA 3
1 Et Et 790 3100 615 431
3 Me Me 699 6910 893 659
4 n-Pr n-Pr 1838 55.5 74.8 80
5 n-Bu n-Bu 43.1 50.9 81.7 72.8
6 n-Hex n-Hex 48.0 51.3 95.4 51.7
7 HOCH2CH2 HOCH2CH2 9.2 4.0 7.5 6.0
8 i-Bu i-Bu 0.97 0.95 86.2 43.0
9 (CH2)5 0.96 27.5 90.5 4.1
10 (NC)(Ph)C(CH2CH2)2 48.4 40.8 93 61.2
11 O[(CH2CH2)]2 0.88 0.95 0.94 0.91
12 Et n-Bu 157 27.8 91.6 63.5
13 Me Ph 39.6 21.5 25.2 46.8
14 Me PhCH2 69.9 25.4 72 62.5
15 H sec-butyl 21.1 29.4 6.0 3.6
16 H Ph 4.8 4.5 5.6 2.5
17 H 2-thiazolyl 3.9 4.6 89.4 9.5
18 H PhCH2 4.1 0.7 7.1 87.3
19 H 4-PyridylCH2 3.5 16.6 5.4 5.7
20 H Imidazol-1-yl-(CH2)3 8.6 24.7 5.3 8.7
21 H O[(CH2CH2)]2N 4.8 3.6 6.1 2.4
22 H O[(CH2CH2)]2N(CH2)2 31.8 36.3 7.1 2.8
23 H [(CH2)5N]CH2CH2 4.5 20.3 9.1 8.8
24 H MeN[(CH2CH2)]2N 33.5 33.0 4.7 2.6
25 NaS(S=C)N[(CH2CH2)]2 12.6 0.92 37.5 0.78
26 H KOOCCH2 13.1 325 7.7 8.0
27 (S)-[CH2CH2CH2CH(COONa)] 2.5 17.3 7.1 6.4
28 H N[(CH2CH2)N]3 31.9 13.5 4.2 4.0
AAZ 250 12 481 104
Reproduced with permission from [22]. © Informa (2013).
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Table 8.4. hCA II, Can2, CaNce103 and CgNce103 inhibition data with 
dithiocarbamates 1, 3–28.
Compound R1 R2 Ki (nM)
hCA II Can2 CaNce103 CgNce103
1 Et Et 3100 802 950 874
3 Me Me 6910 876 962 913
4 n-Pr n-Pr 55.5 88.1 69.4 76.2
5 n-Bu n-Bu 50.9 75.8 67.0 73.2
6 n-Hex n-Hex 51.3 0.75 6.3 3.9
7 HOCH2CH2 HOCH2CH2 4.0 65.5 69.0 70.3
8 i-Bu i-Bu 0.95 6.2 6.0 5.7
9 (CH2)5 0.96 64.5 62.1 72.9
10 (NC)(Ph)C(CH2CH2)2 48.4 7.3 7.2 7.6
11 O[(CH2CH2)]2 0.88 5.4 4.2 7.8
12 Et n-Bu 27.8 7.6 5.7 7.1
13 Me Ph 21.5 15.2 16.8 14.9
14 Me PhCH2 25.4 8.3 6.5 7.4
15 H sec-butyl 29.4 71.3 50.8 88.2
16 H Ph 4.5 4.8 6.4 7.8
17 H 2-thiazolyl 4.6 64.4 58.5 72.3
18 H PhCH2 0.7 21.7 37.3 34.5
19 H 4-PyridylCH2 16.6 5.7 5.3 8.7
20 H Imidazol-1-yl-(CH2)3 24.7 6.7 5.3 7.2
21 H O[(CH2CH2)]2N 3.6 5.6 6.6 9.2
22 H O[(CH2CH2)]2N(CH2)2 36.3 6.6 6.0 8.4
23 H [(CH2)5N]CH2CH2 20.3 5.1 7.5 6.0
24 H MeN[(CH2CH2)]2N 33.0 7.1 7.5 8.4
25 NaS(S=C)N[(CH2CH2)]2 12.6 6.3 7.4 7.7
26 H KOOCCH2 325 50.8 61.3 47.0
27 (S)-[CH2CH2CH2CH(COONa)] 2.5 6.4 6.2 7.2
28 H N[(CH2CH2)N]3 13.5 60.5 466 85.9
AAZ 12 10.5 132 11
Reproduced with permission from [23]. © Elsevier (2013).
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4.2–8.3 nM). Also the monosubstituted DTCs 16 and 19–24 possess very 
good inhibitory properties for all the fungal CAs (Kis 4.8–9.2 nM) (Table 8.4). 
The only exceptions are derivatives 15, 17 and 18 (Kis 21.7–88.2 nM). The 
bis derivative 25 reports good inhibition profile too (Ki 6.3–7.7 nM). Among 
the amino acid derivatives 26 and 27 it is interestingly to note they differ 
for an order of magnitude in inhibiting all the fungal CAs, with the latter 
been the more active (Table 8.4). Finally the tris DTC 28 showed a slightly 
preference for the inhibition of the Can2 and CgNce103 isozymes over the 
CaNce103 with a selectivity of 7.7 and 5.4, respectively. 
Conclusion
The DTCs are indeed a new potent class of CAIs. Their salt character 
provides them good solubility in aqueous media, thus allowing for a vast 
array of biomedical applications such as anti-glaucoma and anti-infectives 
(antibacterial, antifungal agents) or in agriculture. 
The crystallographic experiments of several DTCs in adduct with hCA II 
revealed a new binding mode of these compounds to the enzyme, which 
although similar to that of the classical CAIs, the sulfonamides, is quite 
distinct. The DTCs are monodentate ligands of the Zn(II) ion from the 
enzyme active site, binding to it by means of a sulfur atom at a distance 
Zn-S of 2.3 Å.
In the series of approximately 30 DTCs investigated so far as CAIs, it has 
been observed that small structural modifications in the inhibitor scaffold 
lead to different location of the molecules within the enzyme active site, 
leading also to quite variable SAR for the various isoforms or enzyme 
classes (α- and β-CAs of mammalian, insect, fungal or bacterial origin). 
Such observations are in agreement with the reported kinetic profiles as 
small modifications in the DTC scaffolds account for sensible changes in 
the inhibition potency and selectivity over the CA isozymes tested so far. 
We estimate that in the future more classes and variants of DTCs will be 
investigated as CAIs and that all enzyme classes (apart from the α- and 
β-ones) will be included in such studies.
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Summary. 
 Dithiocarbamates (DTCs) are chemically referred as functional groups analogs to the 
carbamates, containing sulfur instead of oxygen atoms.
 The main feature of DTCs is the ability to form stable complexes with metal and alkali-metal 
ions.
 The rationale of this investigation was to explore whether organic compounds incorporating the 
trithiocarbonate moiety merged into organic scaffolds, such as the DTCs, might act as carbonic 
anhydrase inhibitors (CAIs).
 In any case both DTCs tested proved to be superior in terms of potency and lasting to the 
clinically used DRZ at the same concentration.
 The selective targeting of the β-CAs represents a very promising approach for the development 
of new anti-infectives and the validation of the DTCs as new CAIs indeed might provide such 
opportunity. 
 Their salt character provides them good solubility in aqueous media, thus allowing for a vast 
array of biomedical applications such as glaucoma and anti-infectives or agriculture. 
 The crystallographic experiments of DTC 10, 11 and 14 in adduct with hCA II reveal a binding 
mode similar to the classical CAIs, as the sulfonamides, and also show that small structural 
modifications in the inhibitor determine dissimilar allocation of the molecule portions within the 
enzymatic cleft.
 Such observations are in agreement with the reported kinetic profiles as small modifications in 
the DTC organic scaffolds account for sensible changes in the inhibition potency and selectivity 
over the CA isozymes tested.
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